Scientific Directors

Dr. Torsten Diesinger is Chief Scientific Officer at ACROVIS biostructures.
He studied medicine and philosophy at the University of Ulm (Germany) and Biochemistry and Molecular Cell Biology at the Private University of Witten/Herdecke (Germany).
Already since his doctoral thesis at the Institute of Physiological Chemistry at Ulm University Dr. Torsten Diesinger focused on molecular inhibition mechanisms of drug metabolizing enzymes by small molecules.
Dr. Torsten Diesinger is co-founder of ACROVIS biostructures and holder of a number of patents.

Dr. Radovan Dvorsky studied biochemical biotechnology at the Slovak Technical University in Bratislava were he began his academic career working on quantitative structure-activity relationships of small molecules and antibiotics. Since his PhD study in the field of Biophysical Chemistry at the University of York, UK, and the Comenius University in Bratislava he had focused on Computational Chemistry. He continued his academic career as a Marie-Curie fellow at the Max-Planck Institute for Molecular Physiology in Dortmund, Germany, investigating structural aspects of signaling proteins (Alfred Wittinghofer). Prior to joining ACROVIS he worked as a scientific consultant of Giuliani Pharma, Italy. Dr. Dvorsky is an internationally acknowledged and leading expert in the field of Computer-Aided Drug Design.

Dr. rer. nat. Alfred Lautwein started his academic career as chemist at the University of Mainz and succeeded as a Biochemist at the University of Hannover finishing with his dissertation there. He has been involved in structural biology and the search for drugs and targets at the Max-Planck Institute for Medical Research in Heidelberg (Kenneth Holmes, Roger Goody, Alfred Wittinghofer) and the Max-Planck Institute for Molecular Physiology in Dortmund. During this time he participated in a “National Cooperative Drug Discovery Group for Cancer” of the NIH (USA) in collaboration with the Cetus Corporation and Hoffmann-LaRoche, Nutley. He continued his career in working on cancer and GTP-binding proteins at the Chester Beatty Laboratories for the Cancer Research Campaign in London. Thereafter he worked at biochemical departments at the Universities of Cologne, Tübingen and Ulm contributing to basic research as well as drug target validation (e.g. protease inhibitors for cathepsins).

Dr. Guenter Bartels graduated from the Technical University of Braunschweig (Germany), followed by a Ph.D. in the field of organic chemistry. After a postdoctoral fellowship at the Swiss Federal Institute of Technology in Zurich he started his industrial career at the central research laboratory of Hoechst AG.
Dr. Bartels has more than 25 years experience in industrial organic chemistry. He held positions as head of production of Industrial Organic Chemicals with Riedel-de Haen AG, Germany, director of research and development for Chemical Specialties with AlliedSignal and director of research and development for Pharmaceutical Fine Chemicals with Honeywell. His experience covers the full development stages of organic products from route selection to industrial production.
In 2005 Dr. Bartels founded ASM Research Chemicals as a laboratory services company, which is involved in the development of synthetic routes for new organic compounds and lab scale custom manufacturing.